Bristol-Myers Squibb's Hydrea reduces painful sickle cell anemia episodes by 50% -- NHLBI study.
Executive Summary
BRISTOL-MYERS SQUIBB HYDREA REDUCES PAINFUL SICKLE CELL EPISODES BY 50% leading the National Heart, Lung & Blood Institute to halt the Multicenter Study of Hydroxyurea (MSH) in sickle cell anemia, NHLBI announced Jan. 30. The institute issued a same-day clinical alert to 5,000 U.S. physicians apprising them of the study results. In addition, the National Library of Medicine will place the alert on the MEDLINE system and the document will be faxed to medical school libraries.